This is a list of articles cited by Holtorf as evidence that synthetic hormones causes breast cancer, the list drug companies don’t want you to see: (This list is taken from Dr Dach’s full article on medical ghost writing)
de Lignières B. Effects of progestogens on the postmenopausal breast.
Climacteric. 2002;5(3):229–235.
Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins
and progesterone in hormone replacement therapy and the risk
of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95–108.
Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast
cancer risk in relation to different types of hormone replacement therapy
in the E3N-EPIC cohort. Int J Cancer. 2005;114:448–454.
Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for the
Women’s Health Initiative Investigators. Risks and benefits of estrogen
plus progestin in healthy postmenopausal women: principal results
From the Women’s Health Initiative randomized controlled trial. JAMA.
2002;288(3):321–333.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated
equine estrogen in postmenopausal women with hysterectomy:
the Women’s Health Initiative randomized controlled trial. JAMA.
2004;291(14):1701–1712.
Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen
plus progestin on breast cancer and mammography in healthy postmenopausal
women: the Women’s Health Initiative Randomized Trial.
JAMA. 2003;289(24):3243–3253.
Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE. Estrogen-progestin
replacement therapy and breast cancer risk: the Women’s Health Study
(United States). Cancer Causes Control. 2002;13(9):847–854.
Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogenprogestin
hormone therapy and breast cancer risk. Br J Cancer.
2005;92(11):2049–2058.
Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for
menopausal symptoms and risk of breast cancer. A Danish cohort study.
Br J Cancer. 2005;92(7):1293–1297.
Newcomb PA, Titus-Ernstoff L, Egan KM, et al. Postmenopausal
estrogen and progestin use in relation to breast cancer risk. Cancer
Epid Bio Prev. 2002;11(7):593–600.
Stahlberg C, Pedersen AT, Lynge E, et al. Increased risk of breast
cancer following different regimens of hormone replacement therapy
frequently used in Europe. Int J Cancer. 2004;109(5):721–727.
Li CI. Postmenopausal hormone therapy and the risk of breast cancer:
the view of an epidemiologist. Maturitas. 2004;49(1):44–50.
Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson
I. Breast-cancer risk following long-term oestrogen- and oestrogenprogestin-
replacement therapy. Int J Cancer. 1999;81(3):339–344.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R.
Estrogen-progestin replacement and risk of breast cancer. JAMA.
2000;284(6):691–694.
Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone
replacement therapy on breast cancer risk: estrogen versus estrogen
plus progestin. J Natl Cancer Inst. 2000;92(4):328–332.
Warren MP. A comparative review of the risks and benefits of
hormone replacement therapy regimens. Am J Obstet Gynecol.
2004;190(4):1141–1167.
Weiss LK, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement
therapy regimens and breast cancer risk(1). Obstet Gynecol.
2002;100(6):1148–1158.
Li CI, Malone KE, Porter PL, et al. Relationship between long durations
and different regimens of hormone therapy and risk of breast cancer.
JAMA. 2003;289(24):3254–3263.
Beral V; Million Women Study Collaborators. Breast cancer and
hormone-replacement therapy in the Million Women Study. Lancet.
2003;362(9382):419–427.
Kirsh V, Kreiger N. Estrogen and estrogen–progestin replacement
therapy and risk of postmenopausal breast cancer in Canada. Cancer
Causes Control. 2002;13(6):583–590.
Breast cancer and hormone replacement therapy: collaborative reanalysis
of data from 51 epidemiological studies of 52,705 women with breast
cancer and 108,411 women without breast cancer. Collaborative Group
on Hormonal Factors in Breast Cancer. Lancet. 1997;350(9084):1047–
1059.
Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal
estrogen and estrogen-progestin replacement therapy and breast
cancer risk. JAMA. 2000;283(4):485–491.
Colditz G, Rosner B. Use of estrogen plus progestin is associated with
greater increase in breast cancer risk than estrogen alone. Am J Epidemiol.
1998;147:S45.
Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks
of breast and endometrial cancer after estrogen and estrogen-progestin
replacement. Cancer Causes Control. 1999;10(4):253–260.
Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone
replacement therapy in relation to breast cancer. JAMA.
2002;287(6):734–741.
Pike MC, Ross RK. Progestins and menopause: epidemiological studies
of risks of endometrial and breast cancer. Steroids. 2000;65(10–11-
):659–664.
Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer
with progestins in combination with estrogen as hormone replacement
therapy. J Clin Endocrinol Metab. 2001;86(1):16–23.
Stahlberg C, Pederson AT, Lynge E, Ottesen B. Hormone replacement
therapy and risk of breast cancer: the role of progestins. Acta Obstet
Gynecol Scand. 2003;82(7):335–344.
Olsson HL, Ingvar C, Bladström A. Hormone replacement therapy
containing progestins and given continuously increases breast carcinoma
risk in Sweden. Cancer. 2003;97(6):1387–1392.
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and
progestins and the risk of breast cancer in postmenopausal women. N
Engl J Med. 1995;332(24):1589–1593.
Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years
according to risk factor status: data from the Nurses’ Health Study. Am
J Epidemiol. 2000;152(10):950–964.
To read more on Dr Dach’s work please visit his website at www.jeffreydach.com If you have any questions or comments you can contact him via the website